BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 25310673)

  • 21. Assessment of mitotic rate reporting in melanoma.
    Burton AL; Egger ME; Gilbert JE; Stromberg AJ; Hagendoorn L; Martin RC; Scoggins CR; McMasters KM; Callender GG
    Am J Surg; 2012 Dec; 204(6):969-74; discussion 974-5. PubMed ID: 23036603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
    Nowecki ZI; Rutkowski P; Michej W
    Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases.
    Nagarajan P; Curry JL; Ning J; Piao J; Torres-Cabala CA; Aung PP; Ivan D; Ross MI; Levenback CF; Frumovitz M; Gershenwald JE; Davies MA; Malpica A; Prieto VG; Tetzlaff MT
    Clin Cancer Res; 2017 Apr; 23(8):2093-2104. PubMed ID: 27864417
    [No Abstract]   [Full Text] [Related]  

  • 24. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.
    Scala S; Ottaiano A; Ascierto PA; Cavalli M; Simeone E; Giuliano P; Napolitano M; Franco R; Botti G; Castello G
    Clin Cancer Res; 2005 Mar; 11(5):1835-41. PubMed ID: 15756007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of BRAF mutations in localized cutaneous melanoma.
    Nagore E; Requena C; Traves V; Guillen C; Hayward NK; Whiteman DC; Hacker E
    J Am Acad Dermatol; 2014 May; 70(5):858-62.e1-2. PubMed ID: 24388723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma.
    Ladstein RG; Bachmann IM; Straume O; Akslen LA
    J Invest Dermatol; 2012 Apr; 132(4):1247-52. PubMed ID: 22297638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic role of mitotic rate in cutaneous malignant melanoma: Evidence from a multicenter study on behalf of the Italian Melanoma Intergroup.
    Patuzzo R; Mattavelli I; Gallino G; Galeone C; Valeri B; Mocellin S; Del Fiore P; Ribero S; Mandalà M; Tauceri F; Lombardo M; Maurichi A;
    Cancer; 2023 Aug; 129(15):2331-2340. PubMed ID: 37162404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients].
    de Vries M; Jager PL; Suurmeijer AJ; Plukker JT; van Ginkel RJ; Hoekstra HJ
    Ned Tijdschr Geneeskd; 2005 Aug; 149(33):1845-51. PubMed ID: 16128183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors in young women with cutaneous melanoma.
    Burton AL; Egger ME; Quillo AR; Stromberg AJ; Hagendoorn L; Scoggins CR; Martin RC; McMasters KM; Callender GG
    Am J Surg; 2014 Jan; 207(1):102-8. PubMed ID: 24330977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma.
    Hoersch B; Leiter U; Garbe C
    Br J Dermatol; 2006 Oct; 155(4):771-7. PubMed ID: 16965427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.
    Murali R; Haydu LE; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Thompson JF; Scolyer RA
    Ann Surg; 2012 Jan; 255(1):128-33. PubMed ID: 21975320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A long-term analysis of 620 patients with malignant melanoma at a major referral center.
    Averbook BJ; Russo LJ; Mansour EG
    Surgery; 1998 Oct; 124(4):746-55; discussion 755-6. PubMed ID: 9780997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitotic rate as an important prognostic factor in cutaneous malignant melanoma.
    Piñero-Madrona A; Ruiz-Merino G; Cerezuela Fuentes P; Martínez-Barba E; Rodríguez-López JN; Cabezas-Herrera J
    Clin Transl Oncol; 2019 Oct; 21(10):1348-1356. PubMed ID: 30783917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
    Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
    J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas.
    Gutzmer R; Satzger I; Thoms KM; Völker B; Mitteldorf C; Kapp A; Bertsch HP; Kretschmer L
    J Dtsch Dermatol Ges; 2008 Mar; 6(3):198-203. PubMed ID: 18093216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic importance of the extent of ulceration in patients with clinically localized cutaneous melanoma.
    In 't Hout FE; Haydu LE; Murali R; Bonenkamp JJ; Thompson JF; Scolyer RA
    Ann Surg; 2012 Jun; 255(6):1165-70. PubMed ID: 22566014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors in patients with thick cutaneous melanoma (> 4 mm).
    Zettersten E; Sagebiel RW; Miller JR; Tallapureddy S; Leong SP; Kashani-Sabet M
    Cancer; 2002 Feb; 94(4):1049-56. PubMed ID: 11920475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
    Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
    BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is mitotic rate still useful in the management of patients with thin melanoma?
    Tejera-Vaquerizo A; Pérez-Cabello G; Marínez-Leborans L; Gallego E; Oliver-Martínez V; Martín-Cuevas P; Arias-Santiago S; Aneiros-Fernández J; Herrera-Acosta E; Traves V; Herrera-Ceballos E; Nagore E
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):2025-2029. PubMed ID: 28750139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.
    Clemente CG; Mihm MC; Bufalino R; Zurrida S; Collini P; Cascinelli N
    Cancer; 1996 Apr; 77(7):1303-10. PubMed ID: 8608507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.